CSIMarket
 
Affimed N v   (AFMD)
Other Ticker:  
 
 
Price: $4.5400 $-0.03 -0.656%
Day's High: $5.04 Week Perf: -14.18 %
Day's Low: $ 4.51 30 Day Perf: -21.67 %
Volume (M): 100 52 Wk High: $ 11.10
Volume (M$): $ 456 52 Wk Avg: $5.91
Open: $4.58 52 Wk Low: $2.24



 Market Capitalization (Millions $) 651
 Shares Outstanding (Millions) 143
 Employees -
 Revenues (TTM) (Millions $) 46
 Net Income (TTM) (Millions $) -96
 Cash Flow (TTM) (Millions $) 221
 Capital Exp. (TTM) (Millions $) 1

Affimed N V
Affimed N.V. is a biopharmaceutical company that specializes in the development of innovative antibody-based immunotherapies for the treatment of cancer and other diseases. The company's proprietary technology platform, called ROCK (Redirected Optimized Cell Killing), enables the engineering of antibodies that can selectively target and destroy cancer cells while sparing healthy cells. With a focus on natural killer (NK) cells, Affimed is developing a pipeline of product candidates that have the potential to improve outcomes for patients with various types of cancer. The company is committed to advancing its therapies through clinical trials and bringing them to market to address unmet medical needs.


   Company Address: Technologiepark, Im Neuenheimer Feld 582 Heidelberg 69120 NY
   Company Phone Number: 6221-6743-60   Stock Exchange / Ticker: NASDAQ AFMD
   AFMD is expected to report next financial results on March 22, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Affimed Reports Encouraging Clinical Response Data for AFM24-102 Trial in EGFR-Wildtype Non-Small Cell Lung Cancer

Published Mon, Jan 8 2024 9:05 PM UTC

Affimed N.V., a leading clinical-stage immuno-oncology company, has recently provided an update on the clinical response data for its ongoing AFM24-102 phase 1/2a study in EGFRwt NSCLC (epidermal growth factor receptor-wildtype non-small cell lung cancer). With a commitment to empowering patients in their fight against cancer, Affimed's groundbreaking research and developmen...

Management Announcement

Affimed N.V. Sells Wholly-Owned Subsidiary AbCheck and Works Towards Growth Opportunities in Cancer Immunotherapy

Published Wed, Jan 3 2024 11:30 AM UTC


The announcement follows Affimed's listing transfer to the Nasdaq Capital Market in October 2023, which was seen as a strategic move to unlock new growth opportunities. The transfer, effective from October 4, 2023, allows Affimed to be among a broader range of growth-oriented businesses, providing increased visibility and accessibility to institutional and retail invest...

Clinical Study

Affimed Illuminates Promising Horizon: Revolutionary AFM24 and Atezolizumab Combination Achieves Encouraging Interim Data for Treating Advanced EGFR-wildtype NSCLC.

Published Mon, Dec 11 2023 11:02 AM UTC


Affimed, stationed in Mannheim, Germany, is a trailblazer in the field of cancer immunotherapy with their innovative drug, AFM24. The promising data shed light on possibilities for the significant percentage of NSCLC patients who unfortunately show progression, despite being treated with PD-[L]1 therapy.
Employing AFM24 with Atezolizumab has offered oncologists a ne...

Shares

Affimed N.V. Shifts Listing to Nasdaq Capital Market, Paving the Way for New Era of Growth in Cancer Immunotherapy]

Published Wed, Oct 4 2023 10:30 AM UTC

Affimed N.V. Moves Listing to Nasdaq Capital Market, Unlocking New Growth Opportunities
MANNHEIM, Germany, Oct. 04, 2023 - Affimed N.V. (Nasdaq: AFMD), a pioneering immuno-oncology company, proudly announced today that it has received approval from the Listing Qualifications Department of the Nasdaq Stock Market (Nasdaq) to transfer the listing of its shares from the Nas...






 

Affimed N V's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com